Category: Press Releases

Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy

AUSTIN, Texas and CAMBRIDGE, Mass., April 11, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today the appointment of Julien L. Pham, MD, MPH as the Company's President.

Read More

Genprex to Present at The MicroCap Conference

AUSTIN, Texas, April 6, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today that Rodney Varner, Chairman and CEO, will present at The MicroCap Conference

Read More

Genprex Announces Closing of Initial Public Offering

AUSTIN, Texas, April 4, 2018 /PRNewswire/ -- Genprex, Inc. (NASDAQ:GNPX), a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the closing of its initial public offering on April 3, 2018 of an aggregate of 1,280,000 shares of common stock at a public offering price

Read More

Genprex Announces Pricing of Initial Public Offering of Common Stock

AUSTIN, Texas, March 29, 2018 /PRNewswire/ -- Genprex, Inc., a clinical stage gene therapy company developing immunogene therapy for non-small cell lung cancer, announced today the pricing of its initial public offering on March 28, 2018 of an aggregate of 1,280,000 shares of common stock

Read More

Genprex Files Registration Statement For Proposed Initial Public Offering

AUSTIN, TX, July 21, 2017 – Genprex, Inc. a clinical stage biopharmaceutical company, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock.

Read More

Genprex reports New Pre-Clinical Data Showing Strong Anti-Tumor Effect of TUSC2 in Combination with PD-1 Checkpoint Blockade in Lung Cancer

– TUSC2+PD-1 blockade demonstrates significantly greater anti-tumor effect compared to PD-1 blockade alone –
– TUSC2+PD-1 blockade increases survival in mice and elevates innate immune system activity, including upregulation of natural killer cells and cytotoxic T cells –

Read More

Genprex to Present at Two Upcoming Conferences

Genprex, Inc., a privately held, clinical-stage biopharmaceutical company developing immunogene therapeutics, today announced that Julien Pham, MD, the Company’s Chief Operating Officer, is scheduled to present a corporate overview at two upcoming healthcare investor conferences.

Read More

Genprex Announces Positive Interim Data from Phase II Clinical Trial of Oncoprex™ for Late Stage Non-Small Cell Lung Cancer

Genprex, Inc. today announced positive interim data from an ongoing Phase II clinical trial (NCT01455389) evaluating its investigational immunogene therapy candidate Oncoprex™ in combination with the tyrosine kinase inhibitor (TKI) erlotinib (Tarceva®).

Read More

Genprex To Present at Biotech Showcase 2017

Genprex, Inc. announced that management will be presenting at Biotech Showcase 2017 to be held January 9-11, 2017 in San Francisco, concurrently with the J.P. Morgan Healthcare Conference.

Read More

Genprex Retains ICR Healthcare as Integrated Strategic Communications Counsel

Genprex, Inc. has retained ICR Healthcare, a specialty healthcare practice within a leading strategic communications and advisory firm, to develop and implement an integrated strategic communications program.

Read More

 
STAY IN THE KNOW WITH
EMAIL NEWS ALERTS
 
Don't miss out. Get our news delivered to your inbox.
 

 
close-link
 
Get Email News Alerts
 
close-link